Additional file 2: of VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

  • Maurizio Martini (Catholic University of the Sacred Heart) (Creator)
  • Ivana De Pascalis (Contributor)
  • Quintino Giorgio D'Alessandris (Contributor)
  • Vincenzo Fiorentino (Creator)
  • Francesco Pierconti (Creator)
  • Hany El-Sayed Marei (Creator)
  • Lucia Ricci Vitiani (Creator)
  • Roberto Pallini (Catholic University of the Sacred Heart) (Creator)
  • Luigi Maria Larocca (Fondazione Policlinico Universitario Agostino Gemelli IRCCS) (Creator)

Dataset

Description

Figure S1. Panels A and B. The panels show the significant correlation between plasma level of VEGF-121 and, respectively, OS (panel A; linear regression test: p = 0.0013; r2 = 0,9417), and PFS (panel B; linear regression test: p = 0.0001; r2 = 0,9913). Panels C and D. The panels show the significant correlation between differential plasma value of VEGF-121 (∆VEGF121: VEGF-121 level at baseline – VEGF-121 level after bevacizumab infusion) and, respectively, OS (panel C; linear regression test: p = 0.0008; r2 = 0,9731), and PFS (panel D; linear regression test: p = 0.0003; r2 = 0,9742). (TIF 1478 kb)
Dati resi disponibili2018
Editorefigshare

Accesso dataset

Cita questo